Name: Latest research reports of Zydus Lifesciences Ltd. authored by HDFC Securities and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: HDFC Securities

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

1047.8500 14.05 (1.36%)

NSE Sep 18, 2025 15:31 PM

31.81% Gain from 52W Low

Volume: 977.2K

Zydus Lifesciences Ltd.

29 May 2017

1047.85

1.36%

Cadila (4QFY17): Good times ahead. Upgrade to BUY

Buy: Zydus Lifesciences Ltd.

Target

HDFC Securities

Cadilas (CDH) 4Q performance was unimpressive, with EBITDA margin declining ~389bps YoY to 19.8% and earnings dipping ~32% YoY to Rs 3.8bn.

Geojit BNP Paribas increased Buy price target of Zydus Lifesciences Ltd. to 1121.0 on 03 Sep, 2025.